Richard T. Penson, MD | Authors


SOLO3 Reviews Potential Toxicities With Olaparib in Ovarian Cancer

August 15, 2019

Richard T. Penson, MD, discusses the toxicities that were demonstrated in the long-term follow-up of the phase III SOLO3 trial. This multicenter, open-label trial investigated single-agent olaparib in patients with platinum-sensitive, relapsed, BRCA-mutated ovarian cancer who have received at least 2 prior lines of chemotherapy.